Close menu




January 13th, 2020 | 11:33 CET

Agrios Global Holdings LTD - still on track

  • Cannabis
Photo credits: pixabay.com

Agrios Global Holdings is an agricultural technology company with a focus on the latest innovations in indoor growing and data analytics. The company's technology can be used for all types of indoor cultivation. The company rents and manages real estate and equipment for environmentally sustainable indoor agriculture. The company offers leasing and cultivation services in the field of data-controlled aeroponic cultivation systems for cannabis producers. Furthermore, the company provides consulting services to support the cannabis sector.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA00856K1003

Table of contents:


    Update to the cannabis market

    Agrios Global Holdings (Agrios) is still a young company with high growth potential, according to the experts at GBC Research. The company currently owns a state-of-the-art production facility in Washington State, which is leased to a licensed cannabis producer and processor. Agrios also leases data-driven aeroponics cultivation systems and cultivation services to cannabis producers. The company's technology can also be used for any type of indoor cultivation.

    The US Indoor Aeroponics market is expected to reach USD 40 billion annually by 2022. In addition, the US cannabis market is estimated to reach USD 75 billion annually by 2030. The market in the state of Washington was still around USD 1.37 billion in 2017 and is expected to grow to USD 2.28 billion by 2020.

    Sales increase compared to the previous year

    Agrios Holdings recorded an increase in its product and service revenues and a slight increase in rental / IP revenues in the second quarter of fiscal 2019/2020, which ends March 31, 2020, representing a total increase of 8.54% over the previous quarter to USD 1.093 million compared to USD 1.007 million in the previous quarter.

    Revenues must increase significantly in Q3 and Q4 of the current 2019/2020 financial year in order to meet GBC Research's overall year guidance.

    Still on track

    For the current financial year 2019/2020e, analysts at GBC had previously forecast a small negative after-tax result of USD 1.5 million. They had expected the company to report negative cash flows in the first two quarters of the current 2019/2020 financial year. Only from the third quarter onwards should the operating cash flow turn positive. The company is well on the way to meeting these expectations.

    In the second quarter of 2019, EBITDA was USD -0.524 million, a significant improvement on the previous year's USD -1.789 million. EBIT also showed significant improvements and amounted to USD -0.615 million, which is significantly above the previous year's level of USD -1.843 million. The experts at GBC have raised their price target from CAD 1.38 to CAD 1.64 and confirmed the BUY rating.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET

    Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Cannabis
    • Cancer

    Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.

    Read

    Commented by Armin Schulz on February 8th, 2023 | 11:49 CET

    BioNTech, Pfizer, Cardiol Therapeutics, Bayer - Biotech stocks facing a revival?

    • Biotechnology
    • Cancer
    • vaccine
    • Cannabis

    The BIO Deutschland association represents the German biotech industry. According to an announcement on January 18, financing of biotech companies plummeted by 2/3 in 2022. Overall, the sector raised only EUR 920 million in equity. During the Corona pandemic, many biotech stocks did well. Subsequently, profit-taking occurred and rising interest rates put additional pressure on stocks. That could change in 2023. Meanwhile, some companies are valued low, and so these companies appear on the radar of investors from the United States. According to Handelsblatt, Water Street, an investment company focused on pharma and biotech, has already invested EUR 1 billion, mainly in Germany. A total of EUR 6 billion is to be invested.

    Read

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read